Cite
APA Citation
Shi, R., Filho, S. N. M., Li, M., Fares, A., Weiss, J., Pham, N., Ludkovski, O., Raghavan, V., Li, Q., Ravi, D., Cabanero, M., Moghal, N., Leighl, N. B., Bradbury, P., Sacher, A., Shepherd, F. A., Yasufuku, K., Tsao, M., & Liu, G. (2020). bRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer. Lung cancer, 146, 78–85. http://access.bl.uk/ark:/81055/vdc_100105148159.0x000053